Non-binding Guidance podcast'ini dinle

The Administration's Focus on Direct-to-Consumer Prescription Drug Advertising	Non-binding Guidance	29:04
Trends in False Advertising and Related Competitor Disputes Involving FDA-Regulated Products	Non-binding Guidance	17:11
Clinical Trial Diversity in Focus	Non-binding Guidance	15:11
The Demise of Chevron and Implications for Future APA Challenges	Non-binding Guidance	37:25
FDA Regulatory & Enforcement Risks Relevant to Academic Medical Centers, Health Systems and Research Institutions	Non-binding Guidance	21:43
Preview of the Second Annual Ropes & Gray Rare Disease Forum	Non-binding Guidance	08:39
U.S. Life Sciences Regulatory and Compliance Outlook 2024 (Part IV): Digital Health	Non-binding Guidance	29:08
U.S. Life Sciences Regulatory and Compliance Outlook 2024 (Part III): Advertising and Promotion	Non-binding Guidance	31:17
U.S. Life Sciences Outlook 2024 (Part II): Product Development and Pricing	Non-binding Guidance	33:04
U.S. Life Sciences Regulatory and Compliance Outlook 2024 (Part I): FDA Enforcement and Litigation	Non-binding Guidance	28:10
FDA’s Draft Guidance on Communication of Scientific Information on Unapproved Uses of Medical Products	Non-binding Guidance	24:21
FDA’s Proposed Rule on Laboratory Developed Tests	Non-binding Guidance	23:47
Introducing the U.S. Medical Device Recalls Resource Manual	Non-binding Guidance	07:56
Recent Developments in Oncology Drug Development	Non-binding Guidance	21:24
The Regulatory Landscape for Drug Compounding—10 Years After the NECC Outbreak	Non-binding Guidance	12:33
Key Takeaways from FDA’s Final Guidance on Clinical Decision Support Software	Non-binding Guidance	20:05
Continued Global Pressure on Drug Pricing & Reimbursement and the Next Frontiers for Effective Market Access	Non-binding Guidance	22:25
A Recall Readiness Rundown and Recent FDA Actions	Non-binding Guidance	21:41
Real-World Evidence in Drug Development	Non-binding Guidance	17:35
Recent Developments in FDA Inspection Policy and Implications for Drug and Device Manufacturers	Non-binding Guidance	23:08
Rolling Back the Medicare Coverage of Innovative Technology (MCIT) Rule	Non-binding Guidance	16:33
FDA’s Intended Use Final Rule	Non-binding Guidance	24:18
COVID-19 Vaccine Mandate Litigation	Non-binding Guidance	26:15
The Defense Production Act and the COVID-19 Pandemic	Non-binding Guidance	18:38
European Life Sciences Regulatory Trends with Dr. Lincoln Tsang	Non-binding Guidance	23:49
FDA Regulatory Developments in AI and Machine Learning	Non-binding Guidance	18:15
Real-World Evidence in Drug Development and the Impact of the COVID-19 Pandemic	Non-binding Guidance	17:32
FDA Regulation of COVID-19 Diagnostic Tests and “Return to Work”	Non-binding Guidance	23:50
SEC Disclosure Issues for Life Sciences Companies	Non-binding Guidance	13:29
A Discussion of Kisor v. Wilkie	Non-binding Guidance	27:06
Breakthrough Devices Program	Non-binding Guidance	15:52
Expedited Review Programs for Drugs and Biologics	Non-binding Guidance	13:11
Real-World Evidence in Drug Development and FDA Submissions	Non-binding Guidance	16:20
Examining FDA’s Enforcement Authority Over Stem Cell Clinics and Compounders	Non-binding Guidance	25:12
Former FDA Commissioner Scott Gottlieb’s Unfinished Business	Non-binding Guidance	22:56
FDA’s Regulation of Products Containing CBD	Non-binding Guidance	16:45

The Administration's Focus on Direct-to-Consumer Prescription Drug Advertising

Non-binding Guidance

29:04

Trends in False Advertising and Related Competitor Disputes Involving FDA-Regulated Products

Non-binding Guidance

17:11

Clinical Trial Diversity in Focus

Non-binding Guidance

15:11

The Demise of Chevron and Implications for Future APA Challenges

Non-binding Guidance

37:25